Fulcrum Therapeutics Inc (FULC)

NASDAQ
8.640
+0.140(+1.65%)
After Hours
8.640
0.000(0.00%)
- Real-time Data
  • Volume:
    482,088
  • Day's Range:
    8.420 - 9.030
  • 52 wk Range:
    6.850 - 33.097

FULC Overview

Prev. Close
8.5
Day's Range
8.42-9.03
Revenue
16.96M
Open
8.53
52 wk Range
6.85-33.097
EPS
-2.38
Volume
482,088
Market Cap
353.13M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
729,280
P/E Ratio
-
Beta
-
1-Year Change
-14.05%
Shares Outstanding
40,847,792
Next Earnings Date
Aug 29, 2022
What is your sentiment on Fulcrum Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Fulcrum Therapeutics Inc News

Fulcrum Therapeutics Inc Analysis

Fulcrum Therapeutics Inc Company Profile

Fulcrum Therapeutics Inc Company Profile

Employees
73

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellNeutralSellSellStrong Sell
Technical IndicatorsStrong SellStrong SellBuySellStrong Sell
SummaryStrong SellSellNeutralSellStrong Sell
  • BOING.
    0
    • Careful investors! The technology used by this company is old. This is not a good medium or long term investment; Better is: Crispr, Beam and Intellia.
      2
      • Do you not say the same thing about suppurt systems,,,word for word.
        0
      • Be careful with Bryan the shyster...
        0
    • price target 39$
      1
      • What the heck
        0
        • sell
          0
          • Keep or s?
            0
            • Any n??
              0
              • Any nws?
                0